ReviewMolecular neurobiology2018
Biomarkers in Spinal Cord Injury: from Prognosis to Treatment.
Review in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Research hotspots and trends of microRNAs in spinal cord injury: a comprehensive bibliometric analysis.Frontiers in neurology · 2024Pooled it
- miRNA Therapy in Laboratory Models of Acute Spinal Cord Injury in Rodents: A Meta-analysis.Cellular and molecular neurobiology · 2023Pooled it
- Early CSF Biomarkers and Late Functional Outcomes in Spinal Cord Injury. A Pilot Study.International journal of molecular sciences · 2020Trial
- Analyzing spinal cord injury patients: Directly admitted compared to individuals transferred into level I trauma centers.The journal of spinal cord medicine · 2026Article
- Kinetic and inhibitory profiling of serum MMP-9 in acute spinal cord injury: neurochemical links to injury severity and neuroinflammation.Acta neurologica Belgica · 2026Article
- The Importance of Instrumentation Length in Ankylosing Spinal Disorders and Thoracolumbar Fractures.Journal of clinical medicine · 2026Article
- Integrating bulk and single-cell transcriptome profiling to uncover diagnostic biomarkers and regulatory mechanisms of oxidative stress in spinal cord injury.Neural regeneration research · 2026Article
- Epidemiology of traumatic spinal injuries in a low-resource setting: a retrospective cohort from southwestern Iran.BMC research notes · 2026Article
- Immediate Consequences of a Spinal Cord Injury During Development: Unique Insights From Ex Vivo Models.Neural plasticity · 2026Review
- The clinical application potential of miR-1287-5p in spinal cord injury resulting from spinal trauma and its involvement in modulating the inflammatory response.Journal of orthopaedic surgery and research · 2025Article
- Spinal Cord Injury Remyelination: Pathways to Therapies.International journal of molecular sciences · 2025Review
- Article
- Advances and Challenges in Spinal Cord Injury Treatments.Journal of clinical medicine · 2024Review
- Acute spinal cord injury serum biomarkers in human and rat: a scoping systematic review.Spinal cord series and cases · 2024Article
- ATF3 is a neuron-specific biomarker for spinal cord injury and ischaemic stroke.Clinical and translational medicine · 2024Article
- Steroid inhibited Serpina3n expression which was positively correlated with the degrees of spinal cord injury.Heliyon · 2024Article
- The Accuracy of the S100B Protein Biomarker in the Prognosis of Patients with Acute Spinal Cord Injury.Asian journal of neurosurgery · 2024Article
- Microglial TNFR2 signaling regulates the inflammatory response after CNS injury in a sex-specific fashion.Brain, behavior, and immunity · 2024Article
- Cilostazol protects against degenerative cervical myelopathy injury and cell pyroptosis via TXNIP-NLRP3 pathway.Cell division · 2024Article
- Bu Shen Huo Xue Formula Provides Neuroprotection Against Spinal Cord Injury by Inhibiting Oxidative Stress by Activating the Nrf2 Signaling Pathway.Drug design, development and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is considered an incurable condition, having a heterogenous recovery and uncertain prognosis. Therefore, a reliable prediction of the improvement in the acute phase could benefit patients. Physicians are unanimous in insisting that at the initial damage of the spinal cord (SC), the patient should be carefully evaluated in order to help selecting an appropriate neuroprotective treatment. However, currently, neurologic impairment after SCI is measured and classified by functional examination. The identification of prognostic biomarkers of SCI would help to designate SC injured patients and correlate to diagnosis and correct treatment. Some proteins have already been identified as good potential biomarkers of central nervous system injury, both in cerebrospinal fluid (CSF) and blood serum. However, the problem for using them as biomarkers is the way they should be collected, as acquiring CSF through a lumbar puncture is significantly invasive. Remarkably, microRNAs (miRNAs) have emerged as interesting biomarker candidates because of their stability in biological fluids and their tissue specificity. Several miRNAs have been identified to have their expressions altered in SCI in many animal models, making them promising candidates as biomarkers after SCI. Moreover, there are yet no effective therapies for SCI. It is already known that altered lysophospholipids (LPs) signaling are involved in the biology of disorders, such as inflammation. Reports have demonstrated that LPs when locally distributed can regulate SCI repair and key secondary injury processes such as apoptosis and inflammation, and so could become in the future new therapeutic approaches for treating SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.